Glaxo’s Weight-Loss Petition Relied On “Deeply Flawed” Survey – AHPA
This article was originally published in The Tan Sheet
Executive Summary
The American Herbal Products Association says GlaxoSmithKline used data from a flawed consumer survey when the firm asked FDA to reclassify weight loss claims as disease claims
You may also be interested in...
FDA Warns Of Possible Criminal Charges Against Weight-Loss Product Firms
FDA's enforcement action against 28 weight-loss products found to contain undeclared pharmaceutical ingredients drew applause from GlaxoSmithKline, marketer of alli, the only OTC drug approved for weight loss in the U.S
Petition Requests Pre-Market Approval For Supplement Weight-Loss Claims
Manufacturers would need pre-market approval to make weight-loss claims for supplements if FDA implements a rulemaking recommended by petitioners, including GlaxoSmithKline, the manufacturer of OTC weight-loss drug alli.
Alli Marketing Stresses Education, With Emphasis On Minority Groups – GSK
GlaxoSmithKline’s marketing strategy for its OTC weight-loss drug alli focuses on guiding consumers, particularly African Americans and Hispanics, in deciding whether they will follow the usage protocol before they buy the first-in-class product.